Raised NT-pro-BNP (≥100 pg/ml) level associations with increased all-cause and cardiovascular mortality in early inflammatory polyarthritis
| Model | All-cause mortality HR (95% CI) | CVD mortality HR (95% CI) |
|---|---|---|
| Unadjusted | 4.58 (2.89 to 7.25) | 7.09 (2.91 to 17.30) |
| A | ||
| Age and gender adjusted | 2.36 (1.42 to 3.94) | 3.40 (1.28 to 9.03) |
| B | ||
| Age, gender, hypertension, BMI, diabetes, smoking status, prior CVD | 2.32 (1.36 to 3.96) | 2.71 (1.00 to 7.37) |
| C | ||
| Age, gender, RF and/or ACPA positive, HAQ score, tender joint count, CRP | 2.22 (1.28 to 3.86) | 2.76 (1.00 to 7.63) |
| D | ||
| Fully adjusted model* | 2.15 (1.19 to 3.88) | 2.18 (0.76 to 6.27) |
*Fully adjusted model included age at recruitment, gender, hypertension, BMI, diabetes, smoking status, prior CVD, RF and/or ACPA status, HAQ score, tender joint count and CRP.
ACPA, antibodies to citrullinated protein antigens; BMI, body mass index; CRP, C reactive protein; CVD, cardiovascular disease; HAQ, Health Assessment Questionnaire; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; RF, rheumatoid factor.